Triveni Bio key facts
as of Oct 2026- Developer of a clinical-stage biotechnology company designed to create antibody-based therapies targeting immunological and inflammatory diseases.
- Triveni Bio is valued at approximately $398.1M as of Oct 2026, up 28% since its later-stage round, Jun 2025, per PrivateMarketView’s mark.
- It has raised $231.6M across 2 recorded rounds; the latest was Later Stage VC (Series B) ($115.0M) in Jun 2025.
- Notable investors include Fidelity Management & Research Company, Viking Global Investors, Alexandria Venture Investments, OrbiMed, Goldman Sachs Asset Management — 12 tracked in total.
- 1 institutional filer reports fund marks on Triveni Bio across 6 filings.
- Status: Privately Held (backing).
Up 28% since its later-stage round, Jun 2025 ($310.0M post-money).
- ·The complete investor list: 12 names
- ·Watch Triveni Bio: the Monday email on marks, rounds and moves
Institutional fund marks on Triveni Bio
1 filers · latest May 20261 SEC-registered fund reported 6 fair-value marks on Triveni Bio between May 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Triveni Bio funding rounds
2 roundsWho backs Triveni Bio
12+Triveni Bio valuation
Triveni Bio is valued at approximately $398 million as of Oct 2026. The figure is set by institutional fund marks. The reference point is its later-stage round in Jun 2025, at a $310 million post-money valuation; the current figure is up 28% since.
How much has Triveni Bio raised?
Triveni Bio has raised $232 million across 2 recorded rounds since 2023. The largest was a $91.6 million Series A in Oct 2023; the most recent was an $115 million Series B in Jun 2025.
Institutional holders and vehicles
1 SEC-registered fund reported 6 fair-value marks on Triveni Bio between May 2025 and May 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Triveni Bio investors
12 investors are on record for Triveni Bio, including Fidelity Management & Research Company, Viking Global Investors, Alexandria Venture Investments and OrbiMed. By type, the record holds 5 venture capital firms, 2 asset managers and 1 private equity firm. The Series B in Jun 2025 drew 7 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Mythic Therapeutics ($293 million), City Therapeutics ($285 million) and Convergent Therapeutics ($280 million).
About Triveni Bio
Developer of a clinical-stage biotechnology company designed to create antibody-based therapies targeting immunological and inflammatory diseases. The company offers a genetics-informed antibody discovery and engineering platform, deep insights from human genetic data, and biologics targeting validated disease mechanisms, enabling patients and clinicians dealing with immune and inflammatory disorders access to potentially more effective and precise treatments.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2019
- Employees
- 45
- Website
- triveni.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.